Not finding it? Sign in to also search OpenAlex live.
-
IGF1 and Insulin Receptor Single Nucleotide Variants Associated with Response in HER2-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without a Fasting Mimicking Diet (BOOG 2013-04 DIRECT Trial)2023 Cancers article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Nadia de Gruil, Stefan Böhringer, Stefanie de Groot, Hanno Pijl, Judith R. Kroep, Jesse Joachim Swen
2citations -
Response evaluation of neoadjuvant therapy in MIBC : clinical trial‐derived evidence to guide practice2026 British Journal of Urology article Medicine Bladder and Urothelial Cancer Treatments Open access
Roberto Contieri, Bas W.G. van Rhijn, Richard Cathomas, Anja Lorch, Daniela E. Oprea‐Lager, Paramananthan Mariappan, +3 more
1citations -
Quantitative Diffusion-Weighted Imaging Analyses to Predict Response to Neoadjuvant Immunotherapy in Patients with Locally Advanced Head and Neck Carcinoma
Hedda J. van der Hulst, Joris L. Vos, Laura A. Smit, Roland M. Martens, Regina G. H. Beets‐Tan, Michiel W. M. van den Brekel, +2 more
16citations -
Response to neoadjuvant treatment among rectal cancer patients in a population-based cohort2020 International Journal of Colorectal Disease article Medicine Colorectal Cancer Surgical Treatments Open access
Elizabeth Alwers, Lina Jansen, Jakob Nikolas Kather, Efrat L. Amitay, Hendrik Bläker, Matthias Kloor, +6 more
3citations -
Value of 18F-FDG PET/CT for predicting axillary pathologic complete response following neoadjuvant systemic therapy in breast cancer patients: emphasis on breast cancer subtype
Cornelis Maarten de Mooij, Cristina Mitea, Felix Manuel Mottaghy, Marjolein L. Smidt, Thiemo J. A. van Nijnatten
13citations -
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III Melanoma
Irene L. M. Reijers, Robert V. Rawson, Andrew J. Colebatch, Elisa A. Rozeman, Alex Menzies, Alexander C. J. van Akkooi, +13 more
55citations -
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer2024 Breast Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Bruno Valentin Sinn, Katharina Sychra, M. Untch, Thomas Karn, Marion van Mackelenbergh, Jens Huober, +13 more
8citations -
MRI-Based Radiomics Analysis for the Pretreatment Prediction of Pathologic Complete Tumor Response to Neoadjuvant Systemic Therapy in Breast Cancer Patients: A Multicenter Study
Renée W. Y. Granzier, Abdalla Ibrahim, Sergey P. Primakov, Sanaz Samiei, Thiemo J. A. van Nijnatten, Maaike de Boer, +7 more
42citations -
Abstract P1-10-01: Caveolin gene expression predicts for response and clinical outcomes of patients treated with preoperative paclitaxel-based chemotherapy regimens in early stage breast cancer2020 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Terence Marques Williams, Andreas Schneeweiß, Christian Jackisch, Changxian Shen, Karsten Ernst Weber, Peter Andreas Fasching, +16 more
0citations -
Survival data of PRADO: A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.2022 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Christian U. Blank, Irene L. M. Reijers, Robyn P.M. Saw, Judith M. Versluis, Thomas E. Pennington, Ellen Kapiteijn, +14 more
17citations -
The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.2023 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Irene L. M. Reijers, Alexander Maxwell Menzies, Judith M. Versluis, Robyn P.M. Saw, Winan J. van Houdt, Ellen Kapiteijn, +14 more
10citations -
A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial2020 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Thomas Karn, Tobias Meißner, Karsten Ernst Weber, Christine Solbach, Carsten Denkert, Knut Engels, +19 more
16citations -
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial2023 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
8citations -
BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer2023 Breast Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Marte C. Liefaard, Anna van der Voort, Mette S. van Ramshorst, Joyce Sanders, Shiva Vonk, Hugo M. Horlings, +10 more
6citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
1citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
0citations -
Data from Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
Peter Andreas Fasching, Christopher W. Szeto, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Patricia Spilman, +18 more
0citations -
First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.2020 Journal of Clinical Oncology conference-abstract Medicine Cutaneous Melanoma Detection and Management
Christian U. Blank, Irene L. M. Reijers, Thomas E. Pennington, Judith M. Versluis, Robyn P.M. Saw, Elisa A. Rozeman, +14 more
62citations -
Abstract PS10-07: Pathologic complete response and 3-year survival with or without pertuzumab using real-world data of stage II and III HER2-positive breast cancer
Anna van der Voort, Marte C. Liefaard, Mette van Ramshorst, Erik D. van Werkhoven, Astrid N. Scholten, Jelle Wesseling, +3 more
0citations -
Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer2021 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Bruno Valentin Sinn, Sibylle Loibl, Claus Alexander Hanusch, Dirk-Michael Zahm, Hans‐Peter Sinn, Michael Untch, +16 more
46citations -
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials2024 Clinical Cancer Research article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies
Paul Jank, Thomas Karn, Marion van Mackelenbergh, Judith Lindner, Denise Treue, Jens Huober, +18 more
13citations -
Value of Breast and Axillary Tumor-Infiltrating Lymphocytes for Response to Neoadjuvant Chemo-(Immuno)Therapy in Clinically Node-Positive Breast Cancer2026 Clinical Breast Cancer article Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies Open access
Melissa Lenaerts, Loes F. S. Kooreman, Florien J G van Amstel, P. J. van Diest, Sander M. J. van Kuijk, Ernest J. T. Luiten, +28 more
0citations -
Abstract PD5-08: Tumor immune-cell activity assessed by RNAseq is an independent predictor of therapy response and prognosis after neoadjuvant chemotherapy in HER2 negative breast cancer patients - An analysis of the GeparSepto trial2020 Cancer Research conference-abstract Biochemistry, Genetics and Molecular Biology Breast Cancer Treatment Studies cited by 1 patent
Peter Andreas Fasching, Carsten Denkert, Stephen Charles Benz, Karsten Ernst Weber, Christopher W. Szeto, Jan Budczies, +17 more
1citations